Sagimet Biosciences Inc. Announces 2024 Annual Meeting of Stockholders on June 5, 2024
Ticker: SGMT · Form: DEF 14A · Filed: Apr 18, 2024 · CIK: 1400118
Sentiment: neutral
Topics: Annual Meeting, Proxy Statement, Virtual Meeting, Stockholder Vote, Sagimet Biosciences
TL;DR
<b>Sagimet Biosciences Inc. invites stockholders to its virtual 2024 Annual Meeting on June 5, 2024, urging prompt voting.</b>
AI Summary
Sagimet Biosciences Inc. (SGMT) filed a Proxy Statement (DEF 14A) with the SEC on April 18, 2024. Sagimet Biosciences Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 5, 2024, at 10:00 a.m. Pacific Time. The meeting will be accessible online at https://web.lumiconnect.com/217605655 with the password sagimet2024. The company is encouraging stockholders to vote as soon as possible, regardless of attendance plans. Proxy materials are being offered over the internet as permitted by SEC rules. Questions regarding voting can be directed to General Counsel, Elizabeth Rozek, Esq., at legal@sagimet.com.
Why It Matters
For investors and stakeholders tracking Sagimet Biosciences Inc., this filing contains several important signals. The virtual format aims to increase accessibility for global stockholders, reduce costs, and minimize environmental impact. Encouraging early voting ensures that stockholder interests are represented at the meeting, which is crucial for corporate governance.
Risk Assessment
Risk Level: low — Sagimet Biosciences Inc. shows low risk based on this filing. This filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
Analyst Insight
Stockholders should review the proxy statement for details on proposals and vote their shares promptly to ensure representation.
Key Numbers
- June 5, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders.)
- 10:00 a.m., Pacific Time — Annual Meeting Time (2024 Annual Meeting of Stockholders.)
Key Players & Entities
- Sagimet Biosciences Inc. (company) — Registrant and filer of the proxy statement.
- June 5, 2024 (date) — Date of the 2024 Annual Meeting of Stockholders.
- 10:00 a.m., Pacific Time (time) — Time of the 2024 Annual Meeting of Stockholders.
- https://web.lumiconnect.com/217605655 (url) — Internet address to access the virtual annual meeting.
- sagimet2024 (other) — Password to access the virtual annual meeting.
- Elizabeth Rozek, Esq. (person) — General Counsel to whom voting questions can be directed.
- legal@sagimet.com (email) — Email address for voting inquiries.
- George Kemble, Ph.D. (person) — Executive Chairman of the Board of Directors.
FAQ
When did Sagimet Biosciences Inc. file this DEF 14A?
Sagimet Biosciences Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 18, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Sagimet Biosciences Inc. (SGMT).
Where can I read the original DEF 14A filing from Sagimet Biosciences Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Sagimet Biosciences Inc..
What are the key takeaways from Sagimet Biosciences Inc.'s DEF 14A?
Sagimet Biosciences Inc. filed this DEF 14A on April 18, 2024. Key takeaways: Sagimet Biosciences Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 5, 2024, at 10:00 a.m. Pacific Time.. The meeting will be accessible online at https://web.lumiconnect.com/217605655 with the password sagimet2024.. The company is encouraging stockholders to vote as soon as possible, regardless of attendance plans..
Is Sagimet Biosciences Inc. a risky investment based on this filing?
Based on this DEF 14A, Sagimet Biosciences Inc. presents a relatively low-risk profile. This filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
What should investors do after reading Sagimet Biosciences Inc.'s DEF 14A?
Stockholders should review the proxy statement for details on proposals and vote their shares promptly to ensure representation. The overall sentiment from this filing is neutral.
How does Sagimet Biosciences Inc. compare to its industry peers?
Sagimet Biosciences Inc. operates in the pharmaceutical preparations industry, focusing on developing novel therapeutics.
Are there regulatory concerns for Sagimet Biosciences Inc.?
The filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing the solicitation of proxies for company meetings.
Industry Context
Sagimet Biosciences Inc. operates in the pharmaceutical preparations industry, focusing on developing novel therapeutics.
Regulatory Implications
The filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing the solicitation of proxies for company meetings.
What Investors Should Do
- Review the proxy statement for details on proposals to be voted on at the annual meeting.
- Vote your shares by the deadline to ensure your vote is counted.
- Access the virtual meeting online using the provided URL and password.
Key Dates
- 2024-06-05: 2024 Annual Meeting of Stockholders — Primary event for stockholder voting and company updates.
- 2024-04-18: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.
Year-Over-Year Comparison
This is a Definitive Proxy Statement (DEF 14A) for the 2024 Annual Meeting, following standard SEC filing procedures for such events.
Filing Stats: 4,700 words · 19 min read · ~16 pages · Grade level 11.7 · Accepted 2024-04-18 06:16:55
Key Financial Figures
- $104.7 million — derwritten public offering and received $104.7 million in net proceeds. Proceeds from the offe
- $16.00 — on stock, at a public offering price of $16.00 per share. Including shares issued purs
- $86.2 million — received net proceeds of approximately $86.2 million. ii TABLE OF CONTENTS TABLE OF CO
Filing Documents
- tm2411865-1_def14.htm (DEF 14A) — 803KB
- fc_connect-4c.jpg (GRAPHIC) — 66KB
- ic_internet-4c.jpg (GRAPHIC) — 7KB
- ic_laptop-4c.jpg (GRAPHIC) — 3KB
- ic_mail-4c.jpg (GRAPHIC) — 4KB
- ic_telephone-4c.jpg (GRAPHIC) — 5KB
- lg_sagimetbio-4clr.jpg (GRAPHIC) — 26KB
- px_sagimetproxy1pg01-bw.jpg (GRAPHIC) — 373KB
- px_sagimetproxy1pg02-bw.jpg (GRAPHIC) — 163KB
- 0001104659-24-048534.txt ( ) — 1646KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 24 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 38 iii TABLE OF CONTENTS EQUITY COMPENSATION PLAN INFORMATION 39
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 40 ITEMS TO BE VOTED ON 43 PROPOSAL 1: ELECTION OF CLASS I DIRECTORS FOR A THREE-YEAR TERM EXPIRING IN 2027 43 PROPOSAL 2: RATIFICATION OF APPOINTMENT OF Deloitte & Touche LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR 2024 44 OTHER INFORMATION 45 OTHER MATTERS 45 REQUIREMENTS FOR SUBMISSION OF STOCKHOLDER PROPOSALS FOR NEXT YEAR'S ANNUAL MEETING 45 STOCKHOLDER COMMUNICATIONS TO THE BOARD 45 AVAILABILITY OF MATERIALS 46 PROXY STATEMENT This Proxy Statement, with the enclosed proxy card, is being furnished to stockholders of the Company in connection with the solicitation by our Board of proxies to be voted at our Annual Meeting and at any postponements or adjournments thereof. The Annual Meeting will be held on Wednesday, June 5, 2024, at 10:00 a.m., Pacific Time, via the internet at https://web.lumiconnect.com/217605655, using the password sagimet2024. This Proxy Statement and the enclosed proxy card are first being furnished to our stockholders on or about April 18, 2024. The Notice of Internet Availability of Proxy Materials being mailed to the stockholders is not part of the Proxy Statement. iv TABLE OF CONTENTS GENERAL INFORMATION ABOUT THE MEETING PROXY SOLICITATION Our Board is soliciting your vote on matters that will be presented at the Annual Meeting and at any adjournment or postponement thereof. This Proxy Statement contains information on these matters to assist you in voting your shares. This Proxy Statement and the proxy card are being furnished to our stockholders on or about April 18, 2024. This Proxy Statement and our 2023 Annual Report are available to holders of our Series A common stock at www.astproxyportal.com/ast/27458. If you would like to receive, without charge, a paper copy of our 2023 Annual Report, including the financial statements, please send your request to: General Counsel, Sagimet Biosciences Inc., 155 B